PRESTIGE CONSUMER HEALTHCARE INC. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of $1.05 million for the 3-month period ending 2020-12-31, per its 10-Q filed 2021-02-04.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2021-05-07
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2020-12-31 was $1.05M.
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2020-09-30 was $985.00K.
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2020-06-30 was $309.00K.
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2020-03-31 was -$4.86M.
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2020 was -$4.86M.
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2019 was $0.00.
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2018 was $0.00.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.05M 10-Q · filed 2021-02-04 | $2.04M derived: sum of 2 quarters · filed 2021-02-04 | $2.35M 10-Q · filed 2021-02-04 | -$2.52M derived: sum of 4 quarters · filed 2021-02-04 |
| 2020-09-30 | $985.00K 10-Q · filed 2020-11-05 | $1.29M 10-Q · filed 2020-11-05 | -$3.57M derived: sum of 3 quarters · filed 2020-11-05 | -$3.57M derived: sum of 4 quarters · filed 2021-02-04 |
| 2020-06-30 | $309.00K 10-Q · filed 2020-08-06 | -$4.55M derived: sum of 2 quarters · filed 2020-08-06 | -$4.55M derived: sum of 3 quarters · filed 2021-02-04 | -$4.55M derived: sum of 4 quarters · filed 2021-02-04 |
| 2020-03-31 | -$4.86M 10-K · filed 2020-05-08 | -$4.86M derived: sum of 2 quarters · filed 2021-02-04 | -$4.86M derived: sum of 3 quarters · filed 2021-02-04 | -$4.86M 10-K · filed 2020-05-08 |
| 2019-12-31 | $0.00 10-Q · filed 2021-02-04 | $0.00 derived: sum of 2 quarters · filed 2021-02-04 | $0.00 10-Q · filed 2021-02-04 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $0.00 10-K · filed 2021-05-07 | |||
| 2018-03-31 | $0.00 10-K · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |